0.4651

1.03% -0.0003

Verrica Pharmaceuticals Inc (VRCA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.4654

Offen:

$0.473

24-Stunden-Volumen:

225.15K

Relative Volume:

0.60

Marktkapitalisierung:

$45.28M

Einnahmen:

$5.12M

Nettoeinkommen (Verlust:

$-67.00M

KGV:

-0.3164

EPS:

-1.47

Netto-Cashflow:

$-38.94M

1W Leistung:

-6.65%

1M Leistung:

-17.46%

6M Leistung:

-71.03%

1J Leistung:

-93.22%

1-Tages-Spanne:

$0.4461

$0.4996

1-Wochen-Bereich:

$0.4369

$0.51

52-Wochen-Spanne:

$0.3816

$11.41

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Firmenname

Verrica Pharmaceuticals Inc

Sektor

Healthcare (1155)

Branche

Biotechnology (677)

Telefon

484-453-3300

Adresse

10 NORTH HIGH STREET, WEST CHESTER, PA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-11

Neueste SEC-Einreichungen

VRCA's Discussions on Twitter

Vergleichen Sie VRCA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VRCA Verrica Pharmaceuticals Inc	0.4607	45.28M	5.12M	-67.00M	-38.94M	-1.47
VRTX Vertex Pharmaceuticals Inc	488.05	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	583.76	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	599.84	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.78	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	253.34	26.16B	3.81B	-644.79M	-669.77M	-6.24

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-06	Herabstufung	H.C. Wainwright	Buy → Neutral
2024-11-05	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-07-25	Hochstufung	Needham	Hold → Buy
2023-03-22	Eingeleitet	Jefferies	Buy
2023-02-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2022-05-25	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-05-14	Eingeleitet	RBC Capital Mkts	Outperform
2020-12-24	Bestätigt	H.C. Wainwright	Buy
2020-07-15	Herabstufung	BofA Securities	Buy → Neutral
2020-06-30	Bestätigt	H.C. Wainwright	Buy
2020-06-24	Eingeleitet	Northland Capital	Outperform
2020-03-24	Eingeleitet	Needham	Buy
2019-02-21	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten

Apr 18, 2025

GLP-1 Receptor Agonist Market Is Booming Worldwide 2025-2032: Verrica Pharmaceuticals, AbbVie Inc. - newstrail.com

Apr 18, 2025

Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth - MyChesCo

Apr 18, 2025

Apr 13, 2025

Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN

Apr 13, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Apr 13, 2025

Apr 11, 2025

New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208 - MSN

Apr 11, 2025

Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World

Apr 11, 2025

HC Wainwright Analysts Decrease Earnings Estimates for VRCA - Defense World

Apr 11, 2025

Apr 10, 2025

What is HC Wainwright’s Forecast for VRCA FY2028 Earnings? - Defense World

Apr 10, 2025

Apr 09, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Receives “Neutral” Rating from HC Wainwright - Defense World

Apr 09, 2025

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN

Apr 09, 2025

H.C. Wainwright maintains Neutral on Verrica stock after Q1 update By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 08, 2025

Verrica Pharmaceuticals at Needham Conference: Strategic Restructuring and Growth By Investing.com - Investing.com Canada

Apr 08, 2025

Apr 07, 2025

In face of U.S. stock market selloff, shares of West Chester firm are on the rise - The Business Journals

Apr 07, 2025

Verrica Pharmaceuticals Reports Strong Demand-Led Growth In Ycanth® In Q1 2025 - marketscreener.com

Apr 07, 2025

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025 - The Manila Times

Apr 07, 2025

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in - GlobeNewswire

Apr 07, 2025

Record-Breaking Quarter: YCANTH Crosses 10K Units Milestone with 17% Growth - Stock Titan

Apr 07, 2025

Apr 05, 2025

Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors - MSN

Apr 05, 2025

Apr 03, 2025

Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now - MSN

Apr 03, 2025

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors - The Manila Times

Apr 03, 2025

Verrica Pharmaceuticals appoints new board member - Investing.com Australia

Apr 03, 2025

Apr 02, 2025

Verrica Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada

Apr 02, 2025

Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MyChesCo

Apr 02, 2025

Verrica Pharmaceuticals expands board with new director By Investing.com - Investing.com Canada

Apr 02, 2025

Verrica Pharmaceuticals Appoints Dr. Corcoran as Director - TipRanks

Apr 02, 2025

Verrica Pharmaceuticals expands board with new director - Investing.com

Apr 02, 2025

Strategic Move: Verrica Adds Formation Bio CDO to Board Amid YCANTH Success - Stock Titan

Apr 02, 2025

Verrica Pharmaceuticals to Present at Needham Healthcare Conference - MSN

Apr 02, 2025

Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo

Apr 02, 2025

Apr 01, 2025

Harmony, Lungpacer, Verrica and Arbutus make C-suite hires - The Business Journals

Apr 01, 2025

Mar 31, 2025

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Mar 31, 2025

Exclusive: Verrica Pharmaceuticals CEO Fireside Chat at Major Healthcare Conference - Stock Titan

Mar 31, 2025

Mar 26, 2025

Verrica Pharmaceuticals appoints new CMO to advance skin treatments By Investing.com - Investing.com South Africa

Mar 26, 2025

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer - GlobeNewswire

Mar 26, 2025

Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN

Mar 26, 2025

Verrica Pharmaceuticals appoints new CMO to advance skin treatments - Investing.com

Mar 26, 2025

Dermatology Drug Pioneer Joins Verrica to Accelerate YCANTH Growth - Stock Titan

Mar 26, 2025

Mar 25, 2025

VRCA stock plunges to 52-week low, touches $0.5 - Investing.com

Mar 25, 2025

Mar 19, 2025